REFERENCES
- Ames B. N., Gold L. S. Chemical carcinogenesis — Too many rodent carcinogens. Proc. Natl. Acad. Sci. USA 1990; 87: 772–776
- Ames B. N., Gold L. S., Willett W. The causes and prevention of cancer. Proc. Natl. Acad. Sci. USA 1995; 92: 5258–5265
- Ames B. N., Shigenagg M. K., Gold L. S. DNA lesions, Inducible DNA repair and cell division: Three key factors in mutagenesis and carcinogenesis. Environ. Health Perspect. 1993; 101(Suppl. 225)35–44
- Davies T. S., Monro A. Marketed human pharmaceuticals reported to be tumorgenic in rodents. J. Am. Coll. Toxicol. 1995; 14: 90–107
- Gold L. S., Slone T. H., Ames B. N. What do animal cancer tests tell us about human cancer risk? Overview of analyses of the carcinogenic potency base. Drug Metab. Rev. 1998; 30: 359–404, see especially pp. 364 and 365
- International Agency for Research on Cancer (IARC) Monographs on the evaluation of carcinogenic risk to humans. Suppl. 7, IARC, Lyons 1978
- Fung V., Barrett J. C., Huff J. The carcinogenesis bioassay in perseptive, application in identifying human carcinogens. Environ. Health Perspect. 1995; 103: 680–685
- Toxicity Testing, Strategies to Determine Needs and Priorities. National Academy of Sciences, Washington, DC 1984
- Toxic Ignorance. Environmental Defense Fund, New York 1997
- Karstadt M. Availability of epidemiologic data for chemicals known to cause cancer in animals: An update. Am. J. Ind. Med. 1998; 34: 519–525
- Cellular proliferation and chemical carcinogenesis. Environ. Health Perspect. 1993; 101(Suppl. 5)
- Hasemann J. K., Lockhart J. Relationship between the use of the MTD and study sensitivity for detecting rodent carcinogens. Fundam. Appl. Toxicol. 1994; 22: 382–393
- Office of Technology Assessment, Identifying and regulating carcinogens, Report to U.S. Congress, 1987
- Swenberg J. A., Hoel D. G., Magee P. N. Mechanistic and statistical insight into the large carcinogenesis bioassays on N-nitrosodiethylamine and N-nitrosodimethylamine. Cancer Res. 1991; 51: 6404–6414
- Hammer W., Sjoquist F. Plasma levels of tricyclic antidepressents. Life Sci. 1976; 6: 1895–1903
- Dickey C., Santella R. M., Hattis D., Tang D., Hsu Y., Cooper T., et al. Variability in PAH-DNA adducts in peripheral mononuclear cells: Implications for quantitative cancer risk assessment. Risk Anal. 1998; 17: 649–656
- Rall D. Laboratory animal toxicity and carcinogenesis testing: Underlying concepts, advantages and constraints. Ann. NY Acad. Sci. 1988; 534: 78–83
- Llienfeld D. The silence: The asbestos industry and early occupational cancer research-a case study. Am. J. Public Health 1991; 81: 791–800
- Doll R. Mortality from lung cancer in asbestos workers. Br. J. Ind. Med. 1955; 12: 81–89
- Goodman G., Wilson R. Quantitative prediction of human cancer risk from rodent carcinogenic potencies. A closer look at the epidemiological evidence for some chemicals not definitively carcinogens in humans. Regul. Toxicol. Pharmacol. 1991; 14: 118–146
- National Academy of Sciences, NRC, Environmental Studies Board, Contemporary Pestcide Practices: Report of the Executive Committee. Washington, DC 1975; 66–83
- Dominick D. HCB tolerances: An example of risk-benefit decision making. Decision Making for Regulating Chemicals in the Environment. NAS 50 NRC Environmental Studies Board. 13
- Posthearing memo, A. D. Little. OSHA from the Society of Plastic Industries. August 23, 1974
- Morgenstern R., Pizer W., Shih J. -S. Are we overstating the economic cost of environmental protection?. Resources for the Future. Washington, DC 1998
- Whalen E. Priorities. Summer, 1992; 4–5
- Deceased.
- Reprint requests should be sent to: Dr. James Huff, National Institute of Enviromental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709.